Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
Status:
RECRUITING
Trial end date:
2031-07-30
Target enrollment:
Participant gender:
Summary
The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or the grey zone of Baveno VII criteria.
The main question it aims to answer is:
Does carvedilol reduce hepatic decompensation and mortality in these patients despite the absence of varices needing treatment.
Researchers will compare carvedilol to no carvedilol to see if carvedilol can prevent hepatic decompensation and mortality.
Participants will either take carvedilol or not taking carvedilol for 5 years with regular clinic visit for checkups and investigations, including blood tests, ultrasonography of the liver, upper gastrointestinal endoscopy, transient elastography.
Phase:
PHASE4
Details
Lead Sponsor:
Chinese University of Hong Kong
Collaborators:
Royal Prince Alfred Hospital, Sydney, Australia Shanghai Jiao Tong University School of Medicine Singapore General Hospital University of Malaya University of Palermo